BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prodalim Announced its Q1’2026 Results Presenting Accelerated Growth in the Specialty Ingredients & Solutions Activity11.5.2026 12:03:00 CEST | Press release
SIS revenues (Specialty Ingredients & Solutions) grew 64% in Q1 into 19.7 million dollars (growth of 27% on a LFL1 basis).Group revenue for the quarter grew 4% into 91.5 million dollars.Adjusted EBITDA2 for the SIS activity grew 95% into 3.6 million dollars, reflecting an adjusted EBITDA margin of 18%.Adjusted net profit grew 19% into 3.9 million dollars.Cash flow from operating activities surged into 15.0 million dollars. Tsahi Barak, Chairman of the Board and CEO of the Company, stated: “We are pleased to report a strong quarter during which we continued to successfully implement the company’s business strategy, which emphasizes, among other things, significant and profitable growth in the Specialty Ingredients & Solutions activity and the expansion of Solos’ infrastructure, our dealcoholization division. We believe that the positive momentum in this activity will continue throughout the year, as we continuously work to leverage the many opportunities across the various markets. The
Corpay Partners With BVNK To Add Stablecoin Wallets for Global Customers11.5.2026 12:00:00 CEST | Press release
Corpay, Inc. (NYSE: CPAY), the leading corporate payments company, today announced that it is partnering with stablecoin infrastructure platform BVNK to provide stablecoin wallets and settlement capabilities to its global customer base. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511711546/en/ The integration will enable Corpay’s customers to see a stablecoin balance alongside their fiat balances, and provide customers with embedded stablecoin wallets for sending, receiving, storing, and converting stablecoins within its platform. Customers will now have access to the always-on payment rails that operate beyond the limits of traditional banking hours and systems. Corpay will also integrate stablecoin rails in its treasury operations, reducing reliance on pre-funded accounts, improving capital efficiency, and improving the movement of funds across its global footprint outside of its own proprietary network. Corpay serve
Ant International Highlights Democratising AI and Strengthening Trust in 2025 Sustainability Report11.5.2026 11:17:00 CEST | Press release
Company now provides global account services to 1.6 mn SMEs, and credit access to over 30 mn underserved With the inclusion principle integrated into main innovation projects, Ant International now links 2 bn user accounts with 150 mn merchants through multi-layered partnerships, provides global account services to 1.6 mn SMEs, and helps over 30 mn underserved businesses and individuals access quality credit. As its global payment, global account and embedded finance services expand rapidly, it is accelerating investments in compliance capabilities and advanced security technologies to tackle evolving regulatory and risk environments. From basketball courts in New York to marine protection in Java Indonesia, we build extensive partnerships to protect the environment and empower local communities. Ant International, a leading global digital payment, digitisation and financial technology provider, today published its 2025 Sustainability Report, the 2nd since the Company began independent
Dryad Launches Gen-4-Pro Silvanet Wildfire Sensor, Setting New Standard in Ultra-Early Fire Detection11.5.2026 11:09:00 CEST | Press release
Next-generation technology delivers unmatched detection speed, accuracy, and connectivity for global wildfire prevention Dryad Networks, a global leader in ultra-early wildfire detection technology, today announced the launch and immediate availability of the Gen-4-Pro Silvanet Wildfire Sensor, the fourth generation of its industry-leading Silvanet solution. The new Gen-4-Pro sensor introduces significant advancements in detection capability, energy autonomy, and connectivity—further strengthening Dryad’s mission to protect forests, infrastructure, and communities from the growing threat of wildfires. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260510819235/en/ Silvanet Wildfire Sensor Gen4Pro enables ultra-early wildfire detection and environmental data monitoring. The Silvanet suite is a comprehensive wildfire detection system combining solar-powered gas sensors, a large-scale wireless IoT network, and cloud-based analy
Macnica ATD Europe Acquires Indesmatech to Deepen Engineering Presence Across Northern Europe11.5.2026 11:00:00 CEST | Press release
Strategic acquisition strengthens Macnica ATD Europe’s early-stage engagement, engineering support and coverage across Scandinavia and Northern Europe. Macnica ATD Europe today announced the acquisition of Indesmatech, a pan-European technology and advisory company specializing in advanced semiconductor representation, design-in support and consulting, as well as point click buying services. The acquisition is a strategic move by Macnica ATD Europe to strengthen its commercial and engineering presence across Scandinavia and Northern Europe, adding established regional relationships, in-house engineering capabilities and a proven ecosystem-led approach in line with its already strong presence in the region. It’s business focus areas include IoT, communications and power, embedded computing, memory and ASIC, and audio and sensing applications. This complements Macnica ATD Europe’s existing portfolio and reinforces its ability to support customers across a wide range of technology-driven
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom